45% of Social-Media Peptide Buyers Visited the ER, New Survey Finds

A new survey of 1,000 U.S. peptide users published by telehealth platform Sunlight delivers the first large-scale quantitative picture of the peptide gray market — and the numbers are stark. Nearly half of those who bought peptides from social media or messaging platforms ended up in the emergency room.

The Sunlight Peptide Gray Market Report found that 45% of peptide users who purchased from Telegram, WhatsApp, or social media sellers have visited an emergency room or urgent care for a peptide-related adverse reaction. That is nearly three times the 16% rate across all peptide users in the survey.

“This isn’t a fringe risk,” said Dr. Alexandra Chen, a metabolic health researcher who reviewed the survey methodology for Sunlight. “The gray market operates alongside clinical care. These are patients who have doctors, who tell their doctors what they’re doing — and the doctor still has no visibility into what was actually injected.”

Three-quarters (76%) of social-media buyers told their doctor about their peptide use. Yet the products bought outside the prescription system — often shipped with no peptide name on the label and labeled “for research use only” — remain invisible to clinical oversight.

Read more about broader safety concerns raised by ECRI and ISMP on compounded peptides

Market Channels and Risk Concentration

The survey broke down sourcing channels across all 1,000 respondents:

• Doctor or licensed healthcare provider: 62%
• Online retailer or research chemical website: 30%
• U.S. compounding pharmacy: 30%
• Telegram, WhatsApp, or social media seller: 14.5%
• Overseas supplier (China, South Korea, etc.): 10%
• Friend or coworker: 6%

While medical channels remain the largest single source, the 14.5% buying through social media channels accounts for a disproportionate share of adverse outcomes. The report notes that the DEA has documented social media as a primary channel for unregulated drug sales, and news outlets including NPR have recently reported on buyers in peptide enthusiast groups dealing directly with overseas factory representatives via cryptocurrency.

AI Is Filling the Dosing Gap

Perhaps the most unexpected finding: 75.5% of all peptide users surveyed said they have asked ChatGPT or another AI tool for peptide dosing or mixing instructions.

The finding raises new questions about AI safety guardrails in health contexts, particularly for substances without FDA-approved dosing guidelines. The survey did not evaluate the accuracy of AI-provided dosing advice.

The Knowledge Gap

Peptide users who obtained their products without a doctor were three times more likely to report not knowing what they were injecting. The products often arrive with minimal or no labeling, and the “for research use only” disclaimer — a legal framing the FDA has repeatedly flagged as a loophole — provides no consumer safety information.

Regulatory Context

The survey arrives at a moment of heightened regulatory activity. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled for July 2026 to discuss the regulatory status of several peptide compounds. Meanwhile, HHS Secretary Robert F. Kennedy Jr. has publicly pushed for the FDA to ease peptide restrictions, drawing criticism from safety advocates who point to data like the Sunlight survey as evidence that the current unregulated market is already generating preventable harms.

Peptides like BPC-157, GHK-Cu, and Melanotan II are among the most commonly discussed in gray-market channels, the survey’s sourcing data suggests.

What the Report Doesn’t Cover

The Sunlight survey captures user-reported outcomes and cannot independently verify the composition of gray-market products. Previous laboratory testing by organizations including the ECRI Institute has found gray-market peptide purity as low as 5% with heavy metal contamination. The combination of this survey data with those purity findings paints a picture of a market where both product quality and clinical oversight are failing simultaneously.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.